but with less risk of bioprosthetic valve dysfunction, in patients with small annuli and symptomatic severe aortic stenosis. Presenting the data here at CRT 2025, SMART lead Investigator Howard ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

DurAVR ® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm 2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

(RTTNews) - Medtronic plc (MDT) released the two-year results of the SMall Annuli Randomized ... disabling stroke, and heart failure hospitalization, and continued superior valve performance ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Per GE HealthCare’s estimates, around six million myocardial perfusion imaging (MPI) procedures are undertaken each year in the United States to show blood flow through the heart muscle and ...

Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN ... trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients ...

Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN ... a small annulus can benefit from Evolut's differentiated valve design." AS is stated to be a widespread valvular heart ...

released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMART trial assessed patients with aortic ...